Crane Rosemary A 4

What Happened

• Rosemary A. Crane, a director of Teva Pharmaceutical Industries Ltd. (TEVA), had 14,492 restricted share units (RSUs) convert/exercise into ordinary shares on June 5, 2026. The filing reports the conversion (transaction code M) and a corresponding disposal entry at $0.00, indicating settlement/conversion activity rather than an open‑market sale.

Key Details

• Transaction date: June 5, 2026 (reported on Form 4 filed June 8, 2026).
• Shares involved: 14,492 shares converted/exercised; acquisition price listed as N/A; disposal reported at $0.00 (derivative).
• Shares owned after transaction: Not specified in the filing.
• Footnotes:
  • F1: Ordinary Shares may be represented by American Depositary Shares (1 ADS = 1 Ordinary Share).
  • F2: Each RSU represents a contingent right to receive one ordinary share or, at the committee’s option, cash.
  • F3: These RSUs were granted on June 5, 2025 and vested on June 5, 2026.
• Timeliness: Form 4 was filed June 8, 2026 for a June 5 transaction; this appears to meet SEC Form 4 reporting timing requirements.

Context

• The M transaction code indicates an exercise or conversion of a derivative (here, vested RSUs). The $0.00 disposal entry typically reflects conversion/settlement mechanics (not an open‑market sale), so this does not necessarily indicate selling pressure or a purchase signal. As with most RSU vesting events, this reflects compensation being settled into shares rather than a trade made for investment reasons.